Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206442883> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4206442883 abstract "Abstract Background The accumulation of tau aggregates correlates with and facilitates disease progression in pure and mixed tauopathies such as Progressive Supranuclear Palsy and Alzheimer’s disease. However, a disease‐modifying‐therapeutic targeting tau aggregation has not yet shown success in the clinic. Our target approach is highly differentiated from other programs that are focused on inhibiting tau aggregation and all downstream cascades. We have selected and optimized small molecules capable of targeting tau self‐association (TSA), the first and rate‐limiting step in tau aggregation. We have demonstrated the efficacy of our lead TSA inhibitor in two mouse models of tauopathy (htau mice; tau‐P301L‐JNPL3 mice) in preventive and therapeutic studies. Treatment with the lead TSA inhibitor blocked tau self‐association and formation of large tau aggregates, reduced overall tau accumulation, and rescued impaired motor function in aged mice with pre‐existing tau aggregates. IND‐enabling studies for the lead TSA inhibitor are completing, and a FDA submission is planned for Q1 2022. In this study, we aim to identify acute measures of efficacy in aged homozygous female tau‐P301L‐JNPL3 mice that will be used to model Pharmacokinetics (PK)/Pharmacodynamics (PD) relationship of our TSA inhibitors. Methods Acute dose range‐finding (ADRF) study was performed using multiple routes of administration. C57BL/6 mice (n=30) were either administered vehicle or a single dose of a selected TSA inhibitor ranging from 2 to 200 mg/kg (n = 3 mice/gender/group). Biospecimens were collected at C max . PK studies in C57BL/6 mice will be performed with and without fasting to determine the food effects on bioavailability. Results Serum and brain homogenate samples from the ADRF study are being analyzed to evaluate TSA inhibitor concentrations by LC‐MS/MS. These results will be used to select the dose and route of administration for PK studies in 9 months‐old homozygous female JNPL3 mice. To determine the selective dose for PD evaluations, PK studies will be performed using three doses. Some of the PD measures that will be evaluated are tau self‐association, tau hyperphosphorylation, and motor behavior. Conclusions Understanding PK/PD relationship will be crucial for determining appropriate dosing and target engagement biomarkers in subsequent Phase‐1b studies." @default.
- W4206442883 created "2022-01-26" @default.
- W4206442883 creator A5019159217 @default.
- W4206442883 creator A5030631021 @default.
- W4206442883 creator A5030789444 @default.
- W4206442883 creator A5040711144 @default.
- W4206442883 creator A5053537411 @default.
- W4206442883 creator A5068324801 @default.
- W4206442883 creator A5084866059 @default.
- W4206442883 date "2021-12-01" @default.
- W4206442883 modified "2023-10-16" @default.
- W4206442883 title "Identification of pharmacodynamics readouts through acute dosing of a small molecule inhibitor of tau self‐association in a tauopathy mouse model" @default.
- W4206442883 doi "https://doi.org/10.1002/alz.058326" @default.
- W4206442883 hasPublicationYear "2021" @default.
- W4206442883 type Work @default.
- W4206442883 citedByCount "0" @default.
- W4206442883 crossrefType "journal-article" @default.
- W4206442883 hasAuthorship W4206442883A5019159217 @default.
- W4206442883 hasAuthorship W4206442883A5030631021 @default.
- W4206442883 hasAuthorship W4206442883A5030789444 @default.
- W4206442883 hasAuthorship W4206442883A5040711144 @default.
- W4206442883 hasAuthorship W4206442883A5053537411 @default.
- W4206442883 hasAuthorship W4206442883A5068324801 @default.
- W4206442883 hasAuthorship W4206442883A5084866059 @default.
- W4206442883 hasBestOaLocation W42064428831 @default.
- W4206442883 hasConcept C111113717 @default.
- W4206442883 hasConcept C112705442 @default.
- W4206442883 hasConcept C126322002 @default.
- W4206442883 hasConcept C15744967 @default.
- W4206442883 hasConcept C169760540 @default.
- W4206442883 hasConcept C185592680 @default.
- W4206442883 hasConcept C2776477761 @default.
- W4206442883 hasConcept C2776925932 @default.
- W4206442883 hasConcept C2777288759 @default.
- W4206442883 hasConcept C2777739294 @default.
- W4206442883 hasConcept C2778670691 @default.
- W4206442883 hasConcept C2779134260 @default.
- W4206442883 hasConcept C3017833866 @default.
- W4206442883 hasConcept C502032728 @default.
- W4206442883 hasConcept C71924100 @default.
- W4206442883 hasConcept C98274493 @default.
- W4206442883 hasConceptScore W4206442883C111113717 @default.
- W4206442883 hasConceptScore W4206442883C112705442 @default.
- W4206442883 hasConceptScore W4206442883C126322002 @default.
- W4206442883 hasConceptScore W4206442883C15744967 @default.
- W4206442883 hasConceptScore W4206442883C169760540 @default.
- W4206442883 hasConceptScore W4206442883C185592680 @default.
- W4206442883 hasConceptScore W4206442883C2776477761 @default.
- W4206442883 hasConceptScore W4206442883C2776925932 @default.
- W4206442883 hasConceptScore W4206442883C2777288759 @default.
- W4206442883 hasConceptScore W4206442883C2777739294 @default.
- W4206442883 hasConceptScore W4206442883C2778670691 @default.
- W4206442883 hasConceptScore W4206442883C2779134260 @default.
- W4206442883 hasConceptScore W4206442883C3017833866 @default.
- W4206442883 hasConceptScore W4206442883C502032728 @default.
- W4206442883 hasConceptScore W4206442883C71924100 @default.
- W4206442883 hasConceptScore W4206442883C98274493 @default.
- W4206442883 hasIssue "S9" @default.
- W4206442883 hasLocation W42064428831 @default.
- W4206442883 hasOpenAccess W4206442883 @default.
- W4206442883 hasPrimaryLocation W42064428831 @default.
- W4206442883 hasRelatedWork W2521530521 @default.
- W4206442883 hasRelatedWork W2766048906 @default.
- W4206442883 hasRelatedWork W2766057155 @default.
- W4206442883 hasRelatedWork W2793180732 @default.
- W4206442883 hasRelatedWork W2994914024 @default.
- W4206442883 hasRelatedWork W3115245153 @default.
- W4206442883 hasRelatedWork W3134989973 @default.
- W4206442883 hasRelatedWork W3194901486 @default.
- W4206442883 hasRelatedWork W4220753642 @default.
- W4206442883 hasRelatedWork W4308609257 @default.
- W4206442883 hasVolume "17" @default.
- W4206442883 isParatext "false" @default.
- W4206442883 isRetracted "false" @default.
- W4206442883 workType "article" @default.